[1]周琴, 杨小姣, 石孟琼, 等. 南赤瓟醇提物通过PI3K/Akt/mTOR信号通路促进人宫颈癌Caski细胞凋亡[J].中国临床药理学与治疗学, 2016, 21 (1):42-49.
[2]Ventriglia J, Paciolla I, Pisano C, et al. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives[J]. Cancer Treat Rev, 2017, 59:109-116.
[3]Lin J, Chen LT, Qiu XM, et al. Traditional Chinese medicine for human papillomavirus (HPV) infections: a systematic review[J]. Biosci Trends, 2017, 11(3): 267-273.
[4]卢小丰, 尉小琴, 刘呈雄, 等. RCE-4结构改造及其抗肿瘤活性的研究[J]. 三峡大学学报(自然科学版), 2015, 37(3): 104-107.
[5]Bai CH, He HB, Cheng F, et al. A steroidal saponin RCE-4 inhibits lipopolysaccharide- stimulated inflammatory responses via blocking PI3K/Akt-mediated NF-κB activation in RAW264.7 cells[J]. Applied Mechanics and Materials, 2014, 568-570: 1901-1906.
[6]杨小姣, 邹坤, 尉小琴, 等. 吉祥草中甾体皂苷RCE-4激活p53-ROS通路诱导人肝癌 HepG2细胞凋亡的机制研究[J]. 中药药理与临床, 2016, 32(2): 62-67.
[7]Bai CH, Yang XJ, Zou K, et al. Antiproliferative effect of RCE-4 from Reineckia Carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-κB activation[J]. Naunyn Schmiedebergs Arch Pharmacol, 2016, 389(6):573-584.
[8]杨小姣, 白彩虹, 邹坤, 等. 吉祥草中甾体皂苷RCE-4对宫颈癌裸鼠移植瘤的抑制作用[J]. 第三军医大学学报, 2016, 38(5): 476-482.
[9]Small W Jr, Bacon MA, Bajaj A, et al. Cervical cancer: A global health crisis [J]. Cancer, 2017, 123(13): 2404-2412.
[10]王轶英, 王悦, 乔友林, 等. 中国宫颈癌筛查未来之路—细胞学初筛的弃或守[J].中国实用妇科与产科杂志, 2017, 33(3): 324-326.
[11]李丹温, 玉芳, 刘怡安. 康莱特注射液联合放化疗治疗中晚期宫颈癌50例[J]. 长春中医药大学学报, 2015, 31(1): 151-153.
[12]Mallmann P, Mallmann C. Neoadjuvant and adjuvant chemotherapy of cervical cancer[J]. Oncol Res Treat, 2016, 39(9): 522-524.
[13]Lin WF, Lu JY, Cheng BB, et al. Progress in research on the effects of traditional Chinese medicine on the tumor microenvironment[J]. J Integr Med, 2017, 15(4): 282-287.
[14]中华本草编委会. 中华本草(第8册22卷)[M]. 上海: 上海科学技术出版社,1999:178-180.
[15]Mahapatra DK, Asati V, Bharti SK. MEK inhibitors in oncology: a patent review (2015-Present)[J]. Expert Opin Ther Pat, 2017, 27(8): 887-906.
[16]Richman J, Martin-Liberal J, Diem S, et al. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma[J]. Expert Opin Pharmacother, 2015, 16(9):1285-1297.
[17]Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update[J]. Arch Toxicol, 2015, 89(6): 867-882.
[18]Yang SF, Liu GH. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma[J]. Oncol Lett, 2017, 13(3): 1041-1047.
[19]Asati V, Mahapatra DK, Bharti SK. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives[J]. Eur J Med Chem, 2016, 109: 314-341.
[20]Matson JP, Cook JG. Cell cycle proliferation decisions: the impact of single cell analyses[J]. FEBS J, 2017, 284(3): 362-375.
[21]Lee B, Sandhu S, McArthur G. Cell cycle control as a promising target in melanoma[J]. Curr Opin Oncol, 2015, 27(2): 141-150.
[22]Augereau P, Patsouris A, Bourbouloux E, et al. Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy[J]. Ther Adv Med Oncol, 2017, 9(5): 335-346. |